With its Phase IIb VIVIAD trial fully funded and recruing, Vivoryon ("VVY") leads in next generaon Alzheimer's Disease ("AD") therapy. Targeng both neurotoxic and inflammatory components of AD via glutaminyl cyclase ("QPCT"), varoglutamstat ("PQ912") has already shown efficacy in early disease. A posive outcome in the current Phase IIb trial should provide the basis for substanal licensing deal and even condional approval in 2023E 2024E, Nearer term, with QPCT acvity strongly implica
28 Sep 2020
Leading in Alzheimer's with major deals in pipeline
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Leading in Alzheimer's with major deals in pipeline
Vivoryon Therapeutics N.V. (0R3M:LON) | 0 0 0.4% | Mkt Cap: 102.2m
- Published:
28 Sep 2020 - Author:
-
Pages:
27
With its Phase IIb VIVIAD trial fully funded and recruing, Vivoryon ("VVY") leads in next generaon Alzheimer's Disease ("AD") therapy. Targeng both neurotoxic and inflammatory components of AD via glutaminyl cyclase ("QPCT"), varoglutamstat ("PQ912") has already shown efficacy in early disease. A posive outcome in the current Phase IIb trial should provide the basis for substanal licensing deal and even condional approval in 2023E 2024E, Nearer term, with QPCT acvity strongly implica